Below are the most recent publications written about "alpha-Synuclein" by people in Profiles.
-
Scheiblich H, Eikens F, Wischhof L, Opitz S, J?ngling K, Cser?p C, Schmidt SV, Lambertz J, Bellande T, P?sfai B, Geck C, Spitzer J, Odainic A, Castro-Gomez S, Schwartz S, Boussaad I, Kr?ger R, Glaab E, Di Monte DA, Bano D, D?nes ?, Latz E, Melki R, Pape HC, Heneka MT. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes. Neuron. 2024 Sep 25; 112(18):3106-3125.e8.
-
Gibbons CH, Levine T, Adler C, Bellaire B, Wang N, Stohl J, Agarwal P, Aldridge GM, Barboi A, Evidente VGH, Galasko D, Geschwind MD, Gonzalez-Duarte A, Gil R, Gudesblatt M, Isaacson SH, Kaufmann H, Khemani P, Kumar R, Lamotte G, Liu AJ, McFarland NR, Miglis M, Reynolds A, Sahagian GA, Saint-Hillaire MH, Schwartzbard JB, Singer W, Soileau MJ, Vernino S, Yerstein O, Freeman R. Skin Biopsy Detection of Phosphorylated a-Synuclein in Patients With Synucleinopathies. JAMA. 2024 04 16; 331(15):1298-1306.
-
Farzadfard A, Pedersen JN, Meisl G, Somavarapu AK, Alam P, Goks?yr L, Nielsen MA, Sander AF, Knowles TPJ, Pedersen JS, Otzen DE. The C-terminal tail of a-synuclein protects against aggregate replication but is critical for oligomerization. Commun Biol. 2022 02 10; 5(1):123.
-
Scheiblich H, Dansokho C, Mercan D, Schmidt SV, Bousset L, Wischhof L, Eikens F, Odainic A, Spitzer J, Griep A, Schwartz S, Bano D, Latz E, Melki R, Heneka MT. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021 09 30; 184(20):5089-5106.e21.
-
Scheiblich H, Bousset L, Schwartz S, Griep A, Latz E, Melki R, Heneka MT. Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct a-Synuclein Assemblies. J Immunol. 2021 10 15; 207(8):2143-2154.
-
Brekk OR, Korecka JA, Crapart CC, Huebecker M, MacBain ZK, Rosenthal SA, Sena-Esteves M, Priestman DA, Platt FM, Isacson O, Hallett PJ. Upregulating ?-hexosaminidase activity in rodents prevents a-synuclein lipid associations and protects dopaminergic neurons from a-synuclein-mediated neurotoxicity. Acta Neuropathol Commun. 2020 08 06; 8(1):127.
-
van Diggelen F, Frank SA, Somavarapu AK, Scavenius C, Apetri MM, Nielsen J, Tepper AWJW, Enghild JJ, Otzen DE. The interactome of stabilized a-synuclein oligomers and neuronal proteins. FEBS J. 2020 05; 287(10):2037-2054.
-
Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, Adame A, Trinh I, Kim C, Overk C, Masliah E, Rissman RA. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci. 2018 01 24; 38(4):1000-1014.
-
Tayebi N, Parisiadou L, Berhe B, Gonzalez AN, Serra-Vinardell J, Tamargo RJ, Maniwang E, Sorrentino Z, Fujiwara H, Grey RJ, Hassan S, Blech-Hermoni YN, Chen C, McGlinchey R, Makariou-Pikis C, Brooks M, Ginns EI, Ory DS, Giasson BI, Sidransky E. Glucocerebrosidase haploinsufficiency in A53T a-synuclein mice impacts disease onset and course. Mol Genet Metab. 2017 12; 122(4):198-208.
-
de Boni L, Riedel L, Schmitt I, Kraus TFJ, Kaut O, Piston D, Akbarian S, W?llner U. DNA methylation levels of a-synuclein intron 1 in the aging brain. Neurobiol Aging. 2015 Dec; 36(12):3334.e7-3334.e11.